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Abstract
Introducing new reactivity into living organisms is a major challenge in synthetic biology. Despite 
an increasing interest in both developing aqueous-compatible small molecule catalysts and 
engineering enzymes to perform new chemistry in vitro, the integration of non-native reactivity 
into metabolic pathways for small molecule production has been underexplored. Herein we report 
a biocompatible iron(III) phthalocyanine catalyst capable of efficient olefin cyclopropanation in 
the presence of a living microorganism. By interfacing this catalyst with E. coli engineered to 
produce styrene, we synthesize non-natural phenyl cyclopropanes directly from D-glucose in 
single-vessel fermentations. This process represents the first combination of non-biological 
carbene-transfer reactivity with cellular metabolism for small molecule production.
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The field of synthetic biology is changing how important small molecules are 
manufactured.[1] Using renewable starting materials (e.g. sugar, plant biomass, CO2) 
metabolic engineers overproduce small molecules in single-vessel fermentations by 
optimizing both known and de novo biosynthetic pathways in host microorganisms. Despite 
significant progress in this discipline, a major remaining challenge is engineering organisms 
to access compounds of non-natural origin. This objective is important because many small 
molecules of commercial interest are not currently accessible using known enzymatic 
chemistry. Two strategies have emerged to achieve this goal: engineering non-biological 
reactivity into enzymes and developing non-enzymatic catalysts that can be interfaced with 
cellular metabolism.[2,3]
Exploring the reactivity of carbenes has been particularly fruitful for enzyme engineering 
efforts. Carbene intermediates are accessed and utilized in cells by thiamin diphosphate-
dependent enzymes (Figure 1A).[4] Previous studies have introduced ruthenium carbene 
**This work was supported by the National Institutes of Health (DP2 GM105434), the Searle Scholars Program, and the European 
Commission (Marie Curie IOF fellowship to S. W).
balskus@chemistry.harvard.edu, Homepage: http://scholar.harvard.edu/balskus. 
Supporting information for this article is given via a link at the end of the document.
HHS Public Access
Author manuscript
Angew Chem Int Ed Engl. Author manuscript; available in PMC 2016 June 08.
Published in final edited form as:
Angew Chem Int Ed Engl. 2015 June 8; 54(24): 7106–7109. doi:10.1002/anie.201502185.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
complexes within artificial metalloenzymes for olefin ring-closing metathesis in water and 
phosphate buffer.[5] More recent work by the Arnold and Fasan laboratories has extended 
the types of carbenes involved in enzymatic catalysis to include iron carbenes by 
engineering hemin-binding proteins to catalyze enantioselective olefin cyclopropanation 
with ethyl diazoacetate (EDA) both in vitro and in a whole cell format (Figure 1B).[2b,f,g,6] 
These studies were inspired by the mechanistic similarities between cytochrome P450 
oxene-transfer catalysis and transition metal-mediated carbene-transfer reactions. This work 
provides a biocatalytic route to cyclopropanes, which are found in many bioactive synthetic 
molecules.[7] Despite the success of these engineering efforts, enzymes that utilize 
metallocarbene intermediates have not yet been integrated into engineered metabolic 
pathways.
We envisioned approaching this challenge using biocompatible chemistry: non-enzymatic 
reactions capable of modifying metabolites as they are made by living organisms (Figure 
1C).[3] Here we describe the identification of an iron phthalocyanine catalyst that 
cyclopropanates styrene generated by engineered microbial metabolism. This reaction is 
both a new biocompatible iron-mediated transformation and, to the best of our knowledge, 
the first example of metallocarbene chemistry being interfaced with cellular metabolism for 
small molecule production.
We began our studies by investigating the efficiency of olefin cyclopropanation under 
conditions compatible with the growth of E. coli. We initially examined the 
tetraphenylporphyrin iron(III) chloride (FeTPPCl) catalyzed cyclopropanation of 4-vinyl 
anisole and EDA. This reaction has been previously reported to occur under aqueous 
alkaline conditions using diazomethane, and also in aqueous phosphate buffer (pH 7.0) 
under anaerobic conditions using the hemin cofactor as a catalyst (29% conversion).[2g,8] 
We performed the FeTPPCl-mediated reaction in water, phosphate buffer (pH 7.0) and 
growth media of increasing complexity. We found that while the reaction was moderately 
efficient in water, phosphate buffer and growth media provided significantly higher 
conversions and diastereoselectivities (Table 1). Unlike other biocompatible 
transformations, cyclopropanation proceeded efficiently in the complex medium LB.[3a] The 
reasons for the increased conversion in media relative to water are unclear, however similar 
effects observed for other reactions run in highly ionic solvents are hypothesized to arise 
from rate acceleration due to an increased hydrophobic effect.[9] Finally, the addition of 
bacterial cells (E. coli BL21(DE3), OD600=0.5) had no detrimental effect on product 
conversion or selectivity (Entries 5 and 7).
We next conducted a catalyst screen in M9CA-glucose media containing E. coli (Table 2 
and Table S1). Placing electron-withdrawing and electron-donating substituents on the 
porphyrin ring system influenced product diastereoselectivities but diminished conversion 
relative to FeTPPCl (Entries 2 and 3). Replacement of the four aromatic rings of the TPP 
ring system with aliphatic substituents abolished catalytic activity (Table S1). Hemin was 
unreactive under the reaction conditions (Entry 4), despite being previously reported to 
catalyze this transformation in vitro.[2g] Ferric phthalocyanine (FePcCl), proved to be an 
exceptional cyclopropanation catalyst, affording product in 95% yield (Entry 5). Catalyst 
loading of FePcCl could be reduced to as low as 1 mol% with only a moderate loss in 
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conversion. No product was detected using FeCl3 or in the absence of added catalyst, ruling 
out the possibility that either endogenously biosynthesized metal ion complexes or ferric 
ligands produced by E. coli contribute to catalysis in vivo.
The major byproduct of the reaction at 10 mol% catalyst loading is diethyl maleate, which 
arises from EDA dimerization. Unexpectedly, at lower catalyst loadings we observed a new 
byproduct, diethyl succinate (Figure 2 and Table S2). We hypothesized this product arose 
from E. coli using diethyl maleate as a terminal electron acceptor for anaerobic respiration 
under the progressively oxygen-limiting conditions of the reaction set-up. We also verified 
that living cells were required for diethyl succinate production. The formation of this 
byproduct at 2.5 mol% catalyst loading therefore confirms that the E. coli are alive under 
our optimal reaction conditions.
Having shown that the FePcCl-catalyzed cyclopropanation was compatible with E. coli, we 
next attempted the reaction with styrene generated via bacterial metabolism. Styrene 
production from D-glucose has been achieved in the L-phenylalanine overproducing strain 
E. coli NST74 by introducing two enzymes: L-phenylalanine ammonia lyase from 
Arabidopsis thaliana (PAL2), which converts L-phenylalanine to trans-cinnamic acid, and a 
decarboxylase from Saccharomyces cerevisiae (FDC1) that generates styrene from trans-
cinnamic acid (Figure 3A).[10]
We confirmed that FePcCl was effective under the conditions required for styrene 
production by performing the cyclopropanation reaction with 1.5 mM styrene in phosphate-
limited minimal media (MM1) containing E. coli BL21(DE3) and D-glucose (82% yield, 
1.7:1 dr). Serial dilutions and plate counts directly from cultures with and without reaction 
components showed no difference in survival (Figure S1). Together these results suggested 
that our reaction would be compatible with in vivo styrene production. Accordingly, the 
PAL2 and FDC1 genes were introduced into E. coli NST74 on a single expression plasmid 
(pTrc99A_PAL2-FDC1). Under optimized conditions this strain accumulated 1.65 mM 
styrene in the culture medium over 48 h (Figure S5). We next attempted the 
cyclopropanation reaction by adding FePcCl (2.5 mol%) and EDA (2 equiv) to cultures at 
the point of induction of the styrene-producing pathway (OD600=0.5–0.6, t=0 h). After 48 h 
we observed cyclopropane 1 (44% conversion, 3.0:1 dr). 1H-NMR analysis of the reaction 
extract showed no unreacted EDA and significant levels of EDA byproducts, indicating that 
competing carbene dimerization was likely limiting reaction conversion. This issue was 
circumvented by adding EDA portion-wise over the course of the fermentation, which 
increased the yield of 1 to 81%. By adding an additional equivalent of EDA and extending 
the reaction time to 60 h we obtained 1 in 95% yield by GC (3.5:1 dr, Figure 3B).
We performed a series of control experiments to confirm that cyclopropanation required the 
presence of catalyst, EDA, and living E. coli (Figure 3C). To obtain information about the 
timing and rate of cyclopropanation relative to in vivo styrene production, we analyzed 
product distributions in fermentations with and without the reaction components (Figure 3D, 
Figure S4). In the presence of FePcCl and EDA, styrene reaches a maximum concentration 
of 0.6 mM after 18 h and then steadily depletes as 1 accumulates. Ultimately the 
concentration of 1 equals the concentration of styrene produced in the absence of the 
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reaction components. This observation confirms that the biocompatible cyclopropanation is 
interfaced with styrene output from E. coli and that after 18 h the rate of styrene 
consumption via cyclopropanation likely exceeds that of styrene generation via metabolism. 
This analysis also demonstrates that the reaction components have a minimal effect on the 
overall levels of styrene production. Interestingly, in the absence of FePcCl accumulating 
EDA significantly inhibits styrene production after 12 h (P<0.05), indicating that this 
reagent is toxic to E. coli and that the activity of the catalyst prevents this adverse effect in 
the full reaction (Figure S5). A preliminary investigation of the cyclopropanation using a 
three-phase test suggested that catalysis by FePcCl occurs at a solid-liquid interface as no 
product was detected using polymer-supported styrene (Figure S6). This result indicates that 
FePcCl is likely functioning as a heterogeneous catalyst in this transformation.
We evaluated the scope of the in vivo cyclopropanation by examining other diazoacetate 
derivatives. Accessing additional electron poor (acceptor) carbenes provided cyclopropanes 
2–4 in good isolated yields (Figure 3E). We also re-examined hemin as a catalyst to test the 
extent to which the results of our initial screening procedure predicted catalyst performance 
with metabolically generated styrene. Hemin remained a less efficient cyclopropanation 
catalyst (27% conversion after 60 h, Table S4), confirming the utility of our catalyst 
identification strategy. The low reactivity of hemin also resulted in EDA accumulation, 
which dramatically reduced overall styrene production levels to 0.23 mM. This finding 
shows that the identity of the non-enzymatic catalyst can influence multiple variables of in 
vivo reactions. Overall, these studies not only represent a new route to cyclopropanes but 
also a potential roadmap for the discovery of other biocompatible reactions.
The combined use of enzymatic and non-enzymatic catalysis for chemical synthesis can 
provide unique benefits over the use of chemo- or biocatalysis alone.[3c,11] In the case of this 
biocompatible cyclopropanation, the generation of styrene from D-glucose is attractive as it 
avoids the use of non-renewable petroleum streams. By intercepting biologically-produced 
styrene in the fermentation vessel we also circumvent the challenges associated with its 
isolation, including volatility and reactivity (polymerization during gas stripping).[12] 
Additionally, the use of bench- and air-stable phthalocyanines circumvents the need for 
strictly anaerobic conditions during cyclopropanation (as is required by many engineered 
biocatalysts). This feature is critical for overall cyclopropane production as an aerobic 
growth environment is needed for maximum styrene production by engineered E. coli.[10] 
Notably, this requirement has likely made incorporating cyclopropanating enzymes into 
engineered metabolic pathways challenging.
The use of an inexpensive and highly abundant early transition metal catalyst adds to the 
appeal of this process. Indeed, interactions between microorganisms and iron are widespread 
in natural habitats, and evolutionary pressure to accommodate the reactivity of iron-
containing minerals could account for the biocompatibility of our catalyst. The success of 
this cyclopropanation suggests that iron-mediated reactions are a promising source of new 
biocompatible reactions. Natural microbe-mineral interactions may also be good future 
starting-points for designing additional biocompatible non-enzymatic transformations.
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In summary, we have shown that biocompatible metallocarbene-transfer catalysis and 
engineered metabolism can be combined for small molecule production. Integrating 
metallocarbene chemistry with the metabolism of living organisms represents a new 
approach to constructing non-natural molecules. Important future challenges include 
developing biocompatible, chiral catalysts for enantioselective cyclopropanation and 
engineering pathways for the production of substituted styrene substrates. Finally, other non-
enzymatic reactions that use styrene may also be good targets for biocompatible reaction 
development and allow access to further structural diversity from this single, engineered 
metabolic pathway.
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Figure 1. 
Design of a biocompatible cyclopropanation reaction. A) Carbene intermediates in 
biological catalysis. B) Current approaches for accessing ethyl-2-phenylcyclopropane-1-
carboxylate (1) from styrene using transition metal-mediated carbene chemistry. C) Phenyl 
cyclopropane production from D-glucose by combining in vivo styrene production with 
biocompatible chemistry.
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Figure 2. 
A reaction byproduct reports on E. coli survival under the cyclopropantion reaction 
conditions. Reactions were performed as described in Table 1.
Wallace and Balskus Page 8
Angew Chem Int Ed Engl. Author manuscript; available in PMC 2016 June 08.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 3. 
The biocompatible cyclopropanation reaction can be interfaced with microbial styrene 
production. A) Engineered pathway for styrene production in the L-phenylalanine 
overproducer E. coli NST74. B) Cyclopropanation using metabolically generated styrene. C) 
Cyclopropane production requires all reaction components and living E. coli. D) Metabolite 
production during fermentations. E) Additional cyclopropanes accessed via this approach. 
Metabolite concentrations were determined by GC relative to an internal standard of 1,3,5-
trimethoxybenzene. Yields in Section E are of isolated material from 800 mL cultures. All 
data is shown as an average of three independent experiments to one standard deviation. [a] 
93% isolated yield. [b] 72 h reaction.
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Table 1
FeTPPCl-catalyzed cyclopropanations in aqueous media and in the presence of E. coli.
Entry Growth Medium E.coli cells added? Yield (%) trans:cis
1 H2O no 46 3:1
2 0.1 M K2HPO4 no 77 3.7:1
3 M9-glucose no 71 3.7:1
4 M9CA-glucose no 72 4:1
5 M9CA-glucose yes 75 3.9:1
6 LB no 71 4:1
7 LB yes 70 4:1
Reactions were performed using 4-vinylanisole (5 mM), EDA (10 mM) and FeTPPCl (0.5 mM) in sealed Hungate tubes under an atmosphere of 
air. All cultures were grown in the presence of kanamycin (50 mg/L) and isopropyl β-D-1-thiogalactopyranoside (IPTG; 0.2 mM). E. coli BL21 
cells transformed with an empty pET-29b(+) expression plasmid (OD600= 0.5) were used. Product concentrations in crude culture extracts were 
determined by 1H-NMR relative to an internal standard of 1,3,5-trimethoxybenzene. All data is shown as an average of three experiments to one 
standard deviation.
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Table 2
Catalyst screen in the presence of E. coli.
Entry Catalyst (mol%) Yield (%) 75 trans:cis
1 FeTPPCl (10) 3.9:1
2 Fe(F20TPP)Cl (10) 55 5.1:1
3 Fe(OMe)4TPPCl (10) 7 2.9:1
4 hemin (10) 0 –
5 FePcCl (10) 95 3.4:1
6 FePcCl (5) 93[a] 3.4:1
7 FePcCl (2.5) 90[b] 3.7:1
8 FePcCl (1) 80[b] 4.0:1
Reactions were performed as described in Table 1. All data is shown as an average of three experiments.
[a]24 h reaction.
[b]48 h reaction.
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